Aurora Spine FY Conference Summary Company Overview - **Company Name**: Aurora Spine - **Founded**: 2014, went public in late 2013 - **Core Product**: Zip device, a screwless procedure for single-level lumbar fusion, allowing outpatient surgeries without pedicle screws [4][5] Industry Insights - **Market Focus**: Initially targeted orthopedic and neuro spine markets, later expanded into interventional spine space due to demand for non-fusion technology transitioning to fusion procedures [7][8] - **Patient Journey**: Patients typically progress from primary care to physical therapy and then to interventional markets, highlighting the need for simplified procedures [10] Product Development and Launches - **Product Portfolio Expansion**: - **Apollo Cervical Plate**: Launched in 2026, complements the cervical interbody product offering [12][13] - **DEXA Technology**: Introduced DEXA cervical cage and DEXA-L for lumbar spine, focusing on patient-matched implants for better fusion outcomes [13][15] - **Aero Facet Fusion**: New product aimed at treating facet dysfunction, with potential market size estimated at $40 million [24] - **Biologics Portfolio**: Launched biologics including OsteoGraft, TurboFuse, and OsteoSponge to enhance fusion procedures [17][18] Sales and Marketing Strategy - **Sales Team Expansion**: Plans to hire more territory managers to enhance direct sales efforts in 2026 [11][39] - **Shipping Cost Reduction**: Negotiated new shipping contracts to lower costs, positively impacting profitability [22][45] - **Hybrid Product Offering**: Introduction of disposable instrument kits alongside reusable surgical trays to improve accessibility [42] Financial Performance and Goals - **Sales Performance**: Achieved over $4.4 million in sales for five consecutive quarters, aiming to surpass $20 million in revenue in 2026 [37][38] - **Capital Structure**: 78 million shares outstanding with $2.8 million in debt, positive cash flow from operations, and no immediate plans for raising capital [44] Clinical Research and Evidence - **Clinical Studies**: Ongoing studies to validate the efficacy and safety of products, including multicenter studies on the ZIP device and observational studies on DEXA-C [29][30][31] Future Outlook - **2026 Expectations**: Anticipated milestones include new product launches, increased revenue, and enhanced product performance, driven by a strong foundation and diversified product offerings [47][49]